Articles

A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo

Department of Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm
Department of Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm
Center for Hematology and Regenerative Medicine, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm
Princess Margaret Cancer Centre, University Health Network, Toronto
Department of Applied Physics, Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm
Department of Applied Physics, Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm
Department for Biomedical Engineering and Health Systems, KTH Royal Institute of Technology Stockholm
Department for Biomedical Engineering and Health Systems, KTH Royal Institute of Technology Stockholm
Center for Hematology and Regenerative Medicine, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm
Department of Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm, Sweden; Department of Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Department of Molecular Genetics, University of Toronto
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation, Princess Margaret Cancer Centre, University Health Network, Toronto
Department of Applied Physics, Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden; Department of Microbiology, Tumor and Cell Biology, Science for Life Laboratory, Karolinska Institutet, Stockholm
Center for Hematology and Regenerative Medicine, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden; Center for Cell Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm
Department of Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm, Sweden; Department of Applied Physics, Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden; Department of Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm
Haematologica Early view Feb 10, 2022 https://doi.org/10.3324/haematol.2021.279486